Compare
Baxter International Inc vs Solventum Corp vs Boston Scientific Corp vs Becton Dickinson & Co
| Latest fiscal year | Baxter International Inc BAX | Solventum Corp SOLV | Boston Scientific Corp BSX | Becton Dickinson & Co BDX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-09-30 |
| Revenue | $11.24B | $8.32B | $20.07B | $21.84B |
| Revenue growth (YoY) | +5.7% | +0.9% | +19.9% | +8.2% |
| Gross margin | 30.1% | 53.5% | 69.0% | 45.4% (computed) |
| Operating margin | -2.7% | 26.2% | 18.0% | 11.8% |
| Net margin | -8.5% | 18.7% | 14.4% | 7.7% |
| Net income | -$957.00M | $1.56B | $2.89B | $1.68B |
| EPS (Diluted) | -$1.87 | $8.88 | $1.94 | $5.82 |
| Operating cash flow | $845.00M | $369.00M | $4.53B | $3.43B |
| Free cash flow | $332.00M | -$10.00M | $3.66B | $2.67B |
| Cash & equivalents | $1.97B | $878.00M | $1.97B | $641.00M |
| Total assets | $20.05B | $14.29B | $43.67B | $55.33B |
| Total liabilities | $13.95B | $9.24B | n/a | n/a |
| Shareholders' equity | $6.10B | $5.05B | $24.47B | $25.39B |
| Return on year-end equity | -15.7% | 30.8% | 11.8% | 6.6% |
| Shares outstanding | n/a | 173.49M | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Baxter International Inc | Solventum Corp | Boston Scientific Corp | Becton Dickinson & Co |
|---|---|---|---|---|
| Latest | $11.24B Ended 2025-12-31 | $8.32B Ended 2025-12-31 | $20.07B Ended 2025-12-31 | $21.84B Ended 2025-09-30 |
| 1 year earlier | $10.64B Ended 2024-12-31 | $8.25B Ended 2024-12-31 | $16.75B Ended 2024-12-31 | $20.18B Ended 2024-09-30 |
| 2 years earlier | $10.36B Ended 2023-12-31 | $8.20B Ended 2023-12-31 | $14.24B Ended 2023-12-31 | $19.37B Ended 2023-09-30 |
| 3 years earlier | $10.06B Ended 2022-12-31 | $8.13B Ended 2022-12-31 | $12.68B Ended 2022-12-31 | $18.87B Ended 2022-09-30 |
| 4 years earlier | $12.15B Ended 2021-12-31 | n/a | $11.89B Ended 2021-12-31 | $19.13B Ended 2021-09-30 |